Chromobox homolog 8 (CBX8) Interacts with Y-Box binding protein 1 (YBX1) to promote cellular proliferation in hepatocellular carcinoma cells

Lushan Xiao\textsuperscript{1,2,3,*}, Zixiao Zhou\textsuperscript{1,2,3,*}, Wenwen Li\textsuperscript{1,2,3}, Jie Peng\textsuperscript{5}, Qingcan Sun\textsuperscript{1,2,3}, Hongbo Zhu\textsuperscript{3,6}, Yang Song\textsuperscript{1,2,3}, Jin-Lin Hou\textsuperscript{1,2,3,#}, Jingyuan Sun\textsuperscript{1,4}, Hui-Chuan Cao\textsuperscript{1,4}, Dong Zhongyi\textsuperscript{1,4}, Dehua Wu\textsuperscript{1,4}, Li Liu\textsuperscript{1,2,3,#}

\textsuperscript{1}State Key Laboratory of Organ Failure Research, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
\textsuperscript{2}Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
\textsuperscript{3}Department of Infectious Diseases, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
\textsuperscript{4}Department of Radiation Oncology, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, China
\textsuperscript{5}Department of Oncology, The Second Affiliated Hospital, Guizhou Medical University, Kaili, P.R. China
\textsuperscript{6}Department of Medical Oncology, The First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, P.R. China
\textsuperscript{*}Co-first authors
\textsuperscript{#}Co-senior authors

Correspondence to: Li Liu, Jin-Lin Hou; email: liuli.fimmu@gmail.com, jlhousmu@163.com

Keywords: HCC, CBX8, YBX1, cyclin D1, HCC proliferation

Received: May 18, 2019 Accepted: August 22, 2019 Published: September 8, 2019

Copyright: Xiao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Polycomb group (PcG) proteins have recently been identified as critical regulators in tumor initiation and development. However, the function of CBX8 in human hepatocellular carcinoma (HCC) remains largely unknown. Our study was designed to explore the biological function and clinical implication of CBX8 in HCC. We investigated the interplay between CBX8 and cell cycle through Gene Set Enrichment Analysis and western blotting. Bioinformatics tools and co-immunoprecipitation were used to explore cell cycle regulation. Finally, we studied the expression and clinical significance of CBX8 in HCC through 3 independent datasets. CBX8 was upregulated in HCC and its expression correlated with cell cycle progression. CyclinD1 was downregulated by CBX8 knockdown but upregulated by CBX8 overexpression. YBX1 interacted with CBX8 and regulated the cell cycle. Moreover, targeting YBX1 with specific siRNA impaired CBX8-mediated regulation of CyclinD1. CBX8 overexpression boosted HCC cell growth, while CBX8 knockdown suppressed cell proliferation. Further, YBX1 interacted with CBX8. YBX1 knockdown compromised the proliferation of CBX8 overexpressing cells. CBX8 promotes HCC cell proliferation through YBX1-mediated cell cycle progression and is related to poor HCC prognoses. Therefore, CBX8 may serve as a potential target for the diagnosis and treatment of HCC.

INTRODUCTION

Liver cancer was predicted to be the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality worldwide in 2018, with about 841,000 new cases and 782,000 deaths annually \cite{1}. Hepatocellular carcinoma (HCC), accounting for most (75\%–85\%) of the primary liver
cancers occurring worldwide, remains one of the most prevalent and deadliest human cancers [1]. Despite improvements in surgical resection, liver transplantation, molecular-targeted therapy and immunotherapy, the prognosis of HCC has still remained poor over the last decades [2–4]. HCC is typically diagnosed at an advanced stage and has shown a high recurrence rate, resulting in adverse outcomes in patients [5]. Therefore, it is critical to clarify the molecular mechanisms underlying HCC progression and identify novel therapeutic targets for HCC treatment.

Among pathways and factors involved in the formation and maintenance, the PcG proteins have garnered the attention of researchers [6, 7]. Deregulation and dysfunction of PcG proteins often lead to blockade or inappropriate activation of developmental pathways, enhancement of cellular proliferation, inhibition of apoptosis, and restoration of the cancer stem cell population [7–10]. PcG proteins function principally as two large multisubunit complexes, Polycomb repressive complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2) [7]. Under normal circumstances, PRC1 maintains the histone methylation induced by PRC2 to pass on the inactivation signals where CBX8, also known as human Polycomb 3 (HPC3), functions as a transcriptional repressor as part of PRC1 [7]. CBX8 was shown to inhibit the expression of INK4a/ARF to bypass cell senescence in fibroblasts [11]. PcG proteins have been also shown to exhibit non-polycomb functions, contributing to the regulation of diverse cellular functions [7, 12–14]. Recently, CBX8 has been demonstrated to exhibit oncogenic functions in a non-canonical manner in human malignancies. For instance, Cbx8 acts non-canonically with Wdr5 to promote mammary tumorigenesis [15]. Recently, abnormal expression of CBX8 in multiple tumors was reported. CBX8 play different roles in different tumors [6, 15–21]. However, the mechanism by which CBX8 regulates the malignant growth of HCC remains unclear.

In our study, we aim to explore the expression of CBX8 in HCC and its clinical significance by gene microarrays and bioinformatics tools. To further explore the mechanism by which CBX8 plays a role in HCC, we examined the direct coupling of proteins through bioinformatics tools and co-immunoprecipitation (Co-IP) experiments. Finally, we investigated the biological function of CBX8 in HCC cells through CCK-8, and EdU experiments. We set out to identify the mechanism by which CBX8 regulates the malignant progression of HCC. An additional goal is to understand whether CBX8 can be used as a target to block the malignant progression of HCC.

RESULTS

CBX8 is positively correlated with cell cycle signaling pathway

To dissect the molecular mechanism of CBX8, we carried out Gene Set Enrichment Analysis (GSEA) of The Cancer Genome Atlas (TCGA) cohort and found that CBX8 high expressing groups were enriched for cell cycle-related gene sets (Figure 1A and 1B). To confirm its function in regulating the cell cycle, we detected a series of cell cycle-related genes after interfering with CBX8 and found that CCND1 was significantly down-regulated (Figure 1D, Supplementary Figure 1A), and that CyclinD1 was down-regulated by CBX8-knockdown at the protein level (Figure 1C).

CBX8 interact with YBX1

In order to unveil the mechanism underlying the oncogenic function of CBX8 in modulating the cell cycle, we searched for proteins predicted to interact with CBX8 through BioGRID ([https://thebiogrid.org/](https://thebiogrid.org/)) as well as in the literature, and found that CBX8 may bind to YBX1, ILF3(Interleukin Enhancer Binding Factor 3), TFCP2 (Transcription Factor CP2) and UBE2S (Ubiquitin Conjugating Enzyme E2S) (Figure 2A) [23]. To confirm their interaction, we first tested the correlation between their mRNA expression levels in HCC. As detected in TCGA cohort, CBX8 expression was positively correlated with YBX1 and UBE2S mRNA levels (Figure 2B and Supplementary Figure 2A–2C) (r = 0.3167; P< 0.001 and r=0.3190; P=0.0001). More importantly, it was demonstrated via co-immunoprecipitation (Co-IP) experiments that CBX8 interacted with YBX1 (Figure 2C–2D), rather than with ILF3, TFCP, UBE2S (Supplementary Figure 2D).

CBX8 increase levels of CyclinD1 through YBX1

We explored whether CBX8 can play a role in promoting the cell cycle through YBX1 in HCC cells. Firstly, GSEA results showed that YBX1 targets were enriched in high CBX8 expressing groups (Figure 3A) and YBX1 expression was positively correlated with the cell cycle related genes (Figure 3B). To confirm the association of CBX8 with YBX1 and the cell cycle, we transfected a plasmid containing the CBX8 sequence in Huh7, MHCC-97H and SK-Hep-1 cells, and found that CBX8 overexpression markedly increased the level of CyclinD1, while knockdown of YBX1 with a specific siRNA abrogated its effect (Figure 3C–3D, Supplementary Figure 3A). Moreover, CCND1, the mRNA encoding for CyclinD1, was also regulated by CBX8 and YBX1 in the same manner (Figure 3E–3F, Supplementary Figure 3B).
Figure 1. CBX8 is positively correlated with cell cycle signaling pathway. (A–B) Results of Gene Set Enrichment Analysis (GSEA) were plotted to visualize the correlations between CBX8 cell cycle gene signatures in the TCGA cohort (P < 0.01). (C–D) Both protein and mRNA levels of CyclinD1 in CBX8 Knockdown Huh7 cells, as detected by western blotting and q-RT-PCR.

Figure 2. CBX8 interacts with YBX1. (A) CBX8 may interact with YBX1, as visualized by BioGRID. (B) Correlation between CBX8 mRNA and YBX1 mRNA in TCGA cohort (P = 0.0001). (C) Huh7 cells were transfected with Flag-CBX8 overexpression vector for 48 h. An immunoprecipitation (IP) assay, using an anti-Flag antibody, was used to detect the binding of CBX8 and YBX1. (D) Huh7 cells were transfected with GFP-CBX8 and Flag-YBX1 overexpression vector for 48 h. An IP assay, using an anti-Flag antibody, was used to detect the binding of CBX8 and YBX1.
Figure 3. CBX8 increase levels of CyclinD1 through YBX1. Results of GSEA were plotted to visualize the correlation between the expression of CBX8 (A) or YBX1 (B) and gene signatures of YBX1 target up or KEGG cell cycle in the TCGA cohort (P < 0.01). (C–F) Both protein and mRNA levels of CyclinD1 in Huh7 and MHCC-97H cells-overexpressing CBX8 or YBX1 knock-down as detected by western blotting and q-RT-PCR.
Moreover, when we interfered with CBX8 and simultaneously overexpressed YBX1 in Huh7 cells, YBX1 rescued the down-regulation of CBX8-induced CCND1 down-regulation (Supplementary Figure 3C). Therefore, CBX8 promotes the expression of CyclinD1 in a YBX1-dependent manner.

**CBX8 promotes HCC cell proliferation in vitro and in vivo**

Next, whether CBX8 plays a role in the cell proliferation was evaluated. As depicted by CCK-8 and EdU assay, MHCC-97H cells overexpressing CBX8 showed enhanced proliferation compared with the control group (Figure 4A–4C). Another two HCC cell lines, Huh7 and SK-Hep-1 also showed increased cell growth after overexpressing CBX8 (Figure 4D–4F, Supplementary Figure 4A–4C).

To further confirm the regulatory function of CBX8 in the cell proliferation, we knocked down CBX8 and detected the changes of proliferation in MHCC-97H, Huh7 and SK-Hep-1 cells. In three cell lines, knockdown of CBX8 reduced the proliferation rate as compared with the control groups (Figure 5A–5B, Supplementary Figure 5A–5C). Results of EdU assay revealed that cells with CBX8 knockdown were stagnated before S phase of the cell cycle (Figure 5C–5F, Supplementary Figure 5D–5E). Furthermore, the effect of CBX8 knockdown on tumor growth in vivo was examined using mouse subcutaneous xenograft models. Tumor xenografts derived from CBX8 knockdown MHCC-97H and SK-Hep-1 cells exhibited smaller volumes, lower weights, and formed more slowly than tumors obtained from the control cells (Figure 6A–6C and Supplementary Figure 6A–6D). In summary, CBX8 promotes HCC cell proliferation in vitro and in vivo.

![Figure 4. CBX8 overexpression promotes cell proliferation.](image-url)

(A and D) Cell proliferation was evaluated by the CCK-8 assay. (B–F) Effect of CBX8 on cell proliferation as measured by EdU assays *P < 0.05; **P < 0.01; ***P < 0.001.
Figure 5. Knockdown of CBX8 dramatically decreases the cell proliferation in vitro. (A and B) Cell proliferation was evaluated by the CCK-8 assay. (C–F) Effect of CBX8 on cell proliferation as measured by EdU assays *P < 0.05; **P < 0.01; ***P < 0.001.
CBX8 promotes HCC cell proliferation through YBX1

Given that CBX8 regulated CyclinD1 expression through YBX1, we hypothesize that its regulatory function in cell proliferation is YBX1-dependent. We repeated the EdU assay in Huh7, MHCC-97H and SK-Hep-1 cells overexpressing CBX8 with or without simultaneous knockdown of YBX1 with targeted siRNA. Results showed that the increased proliferation of Huh7, MHCC-97H and SK-Hep-1 cells induced by CBX8 overexpression was attenuated by interfering YBX1 (Figure 7A–7D, Supplementary Figure 7A, 7C). Furthermore, when we interfered with CBX8 and simultaneously overexpressed YBX1 in Huh7 cells, YBX1 rescued the effect of CBX8 down-regulation on the inhibition of cell proliferation (Supplementary Figure 7B, 7D). These results confirm that CBX8 promoted cell proliferation in a YBX1-dependent manner.

CBX8 expression is up-regulated in HCC and is correlated with prognosis

As CBX8 plays a significant role in cell proliferation, we next explored its clinical importance. Clinical data of a cohort containing 369 HCC cases and 50 non-tumor cases were obtained from TCGA website (https://www.cancer.gov), and analysis revealed that CBX8 was upregulated in HCC lesions when compared with normal tissues (Figure 8A). We also analyzed another cohort (GSE14520) from GEO database and discovered that in comparison with non-tumor tissues, HCC lesions exhibited higher levels of CBX8 mRNA (Figure 8B). To confirm these results, we compared its expression in 8 pairs of HCC tissues and adjacent normal liver tissues. Accordingly, CBX8 was overexpressed at both mRNA and protein levels in the tumor (Figure 8C–8D). Not only in HCC, but CBX8 expression was increased in pan-cancer as compared with the corresponding non-tumor tissues (Supplementary Figure 8A).

Then, we sought to determine the clinical significance of CBX8 and performed a series of Kaplan-Meier survival analyses. In the TCGA cohort, patients with high CBX8 expression suffered shortened overall survival and disease-free survival (Figure 8E–8F). We further grouped these patients with different pathological features followed by survival analyses. Results showed that CBX8 was of significant

Figure 6. Knockdown of CBX8 dramatically decreases cell proliferation in vivo (A) Representative images of tumors formed in nude mice subcutaneously injected with CBX8-silenced MHCC-97H cells. (B) Tumor weights (**P <0.001). (C) Tumors induced by CBX8 silencing in MHCC-97H cells (**P <0.001) showed markedly lower growth rates than the control cells.
prognostic value in HCC patients at the early and especially the advanced stages (Supplementary Figure 9A–9B). While HCC is often developed from an infection of hepatitis virus or alcohol abuse, CBX8 expression was also potent in clarifying prognosis in patients with viral or toxic pathogeny (Supplementary Figure 9C–9F). Nonetheless, high CBX8 expression indicated poor prognosis in patients with vascular invasion rather than in those without (Supplementary Figure 9G–9H). Furthermore, in patients undergoing sorafenib treatment, CBX8 expression was also a factor markedly effecting their survival (Supplementary Figure 7. CBX8 promotes HCC cell proliferation through YBX1. (A–D) Cell proliferation, as detected by EdU assays **p < 0.01; ***p < 0.001.
Figure 8. CBX8 expression is up-regulated in HCC and is correlated with poor prognosis. (A–B) Expression of CBX8 in the TCGA and GSE14520 cohorts (P < 0.001) (C) Expression levels of CBX8 in HCC tissues and adjacent non-tumor tissues (NFYY cohort) as measured by qRT-PCR analysis (P < 0.05); β-actin was used as an internal control. Data are shown as median with interquartile range. (D) The protein expression of CBX8 in 8 HCC samples was determined by western blotting. (E, F) Kaplan-Meier analysis of the overall and disease-free survival in the TCGA cohort based on CBX8 expression (G, H) Kaplan-Meier analysis of the overall and disease-free survival in the TCGA cohort based on CBX8 and YBX1 expression.
Figure 9I). Our current data indicated that CBX8 regulates cell proliferation through YBX1, and patients with simultaneous high CBX8 and YBX1 expression also had shorter survival and poorer prognosis (Figure 8G–8H). YBX1 was also upregulated in HCC tissues (Supplementary Figure 10A–10B), YBX1 was only capable of predicting overall survival but incapable of disease-free survival (Supplementary Figure 10C–10D). However, YBX1 expression could distinguish between the overall survival curves of patients with various pathological features (Supplementary Figure 11A–11I).

DISCUSSION

The key finding of the current study was that CBX8 promotes cell proliferation and the cell-cycle progression by interacting with YBX1. Our results showed that CBX8 is overexpressed in HCC tissues as compared to corresponding adjacent non-tumor tissues from 3 independent cohorts. Moreover, patients with simultaneous overexpression of CBX8 and YBX1 featured shorter survival and poorer prognosis. Thus, our results indicated that CBX8 may serve as a potential target for the diagnosis and treatment of patients with HCC.

Dysregulation of CBX8 has been reported in various human cancers [15, 16, 20–22, 24]. Growing research has shown the cell proliferation promoting effects of CBX8 in different types of cancers [15, 18, 20]. Unlashed cell proliferation is the hallmark of cancer, and tumor cells have typically acquired damage of genes that directly regulate their cell cycles [25, 26]. Genetic alterations affecting Cyclin D1, and control exit from the G1 phase of the cell cycle, are frequently documented in human cancers and inactivation of this pathway may as well be necessary for tumor development [25, 27]. Interestingly, we found that CBX8 is involved in the cell cycle signaling pathway and regulates the expression of Cyclin D1 in HCC cells.

Also, our research found that CBX8 regulated the cell cycle through YBX1. The Y-box binding protein (YBX1) is known to be a multifunctional transcription and translation factor regulating protein expression; its aberrant activation thus influences various malignant phenotypes of cancer cells [28–32]. For example, it is involved in promoting cancer progression, cell proliferation and multidrug resistance [29, 32–34]. Our study uncovered its interaction with CBX8. Their interaction was predicted by bioinformatics tools and further confirmed with Co-IP and other experiments. Moreover, the function of CBX8 in driving the cell cycle progression and cell proliferation was impaired upon YBX1 knockdown. Therefore, we summarized that CBX8 regulates the cell cycle progression through YBX1 in HCC.

We also found distinctive upregulation of CBX8 in fresh tissues, identified by qRT-PCR and western blot analyses. In TCGA cohorts, patients with high CBX8 expression experienced significantly shorter overall and disease-free survival, as compared with the low CBX8 expression group. Taken together, these findings suggested the misregulation of CBX8 is a potential biomarker for clinical surveillance of tumor progression. Zhang’s and Bo Tang’s reports are consistent with our results and have further confirmed the reliability of our results. However, the mechanisms of malignant HCC progression are different [18, 22]. We first found a new important binding partner for CBX8, and found that CBX8 regulates the proliferation of HCC cells through the regulation of cell cycle pathways. Moreover, we discovered that CBX8 represent a better predictor for poor prognosis of tumors, especially in case of staging, co-occurrence with hepatitis, and when the tumor is treated with sorafenib. More importantly, we found that the simultaneous overexpression of CBX8 and YBX1 is an excellent predictor of poor prognosis in HCC cases. This novel marker may serve as a potential target for the diagnosis and treatment of patients with HCC in the future.

In summary, we identified CBX8 as an oncogene with prognostic significance in HCC. CBX8 promotes HCC progression through activating the expression of Cyclin D1 by binding to YBX1. Our study provides, for further evaluation, a novel therapeutic target for hepatocellular carcinoma treatment. However, our research also has some limitations, for example, the lack of multi-center and large sample sets for verification, limits the validity of our findings. In the future, more clinical samples will be used to verify the results. Moreover, the mechanisms surrounding CBX8 need further exploration, such as the mechanisms by which CBX8 affects Cyclin D1 through YBX1. Of note, synthetic inhibitors are also essential tools to explore the role of CBX8 in HCC. For instance, inhibitors of EZH2, a vital member of the PRC2 complex, play a role in multiple tumors, and specific inhibitors are currently under clinical trial [35–40].

MATERIALS AND METHODS

Human HCC samples

“NFYY cohort”: HCC samples and paired non-cancerous specimens from 8 HCC patients who underwent hepatectomies between January 2012 and January 2013 at Nan fang Hospital, Southern Medical University (Guangzhou, China) were included in this study. Tissues were frozen with liquid nitrogen instantly after hepatectomies and stored in a refrigerator at –80°C. The study was reviewed and approved by the Nan fang Hospital Institutional Review Board.
**Cell lines**

SK-Hep-1, Huh7 and MHCC-97H cells were obtained from the Cell Bank of Type Culture Collection (Chinese Academy of Sciences, Shanghai, China). Cells were cultured under the conditions advised by the supplier.

**Animal studies**

A subcutaneous xenograft model was established to determine the effect of CBX8 on tumor growth in vivo. BALB/c nude mice (males, 4–5-weeks-old) were purchased from the Central Laboratory of Animal Science, Southern Medical University (Guangzhou, China). Experimental procedures in this study were performed according to our institutional guidelines for using laboratory animals and were approved by the Institutional Animal Care and Use Committee of Nanfang Hospital. In total, 1 × 10^7 MHCC-97H, SK-Hep-1 stably expressing sh-CBX8, and vector control were subcutaneously injected into the flank of the mice (Genechem Company Ltd., Shanghai, China). After 25 days, the mice were sacrificed. Tumor growth was examined every 2-3 days. Tumors were weighed after removal.

**Bioinformatics analysis**

“TCGA cohort”: A cohort from the TCGA (https://tcga-data.nci.nih.gov/tcga/) database including 369 HCC patients with CBX8 and YBX1 as well as follow-up information was included in our study to explore the expression levels of CBX8 and YBX1 in HCC. (Overall survival) OS and (Disease-free survival) DFS were also assessed according to CBX8 or YBX1 expression levels as follows: patients were split into two groups on the basis of CBX8 expression status in the primary tumor. Those with a CBX8-expression level ranked in the top quartile were classified into the high expression group and the rest into the low expression group [41–43].

“GSE14520 cohorts”: microarray data (GEO accession numbers GSE14520 were downloaded from the GEO (http://www.ncbi.nlm.nih.gov/geo/) to validate CBX8 or YBX1 expression level in HCC. [24] GCBI (GeneCloud of Biotechnology Information) (Shanghai, China, https://www.gcbi.com.cn) is a data analysis website. In this study, we used GCBI to identify relative CBX8 mRNA expression in human cancers. Stratified analysis showed the correlation of CBX8 or YBX1 and survival in liver cancers was analyzed in Kaplan–Meier Plotter (http://kmplot.com/analysis/) [44].

CCK-8 and EdU Assays, qRT-PCR, Plasmid Construction and Transient Transfection, Western Blot, RNA interference, Co-Immunoprecipitation (Co-IP), Lentiviral Construction and Cell Transfection; these were performed as described previously and are detailed in the Supplementary Methods.

**Statistical analysis**

Data are presented as the mean ± standard error of the mean (SEM) from three independent experiments, except when indicated otherwise. The t-test or one-way analysis of variance (ANOVA) for comparison of two groups, multi-way classification ANOVA for cell proliferation, Pearson’s correlation for analyzing the correlation between CBX8 and YBX1, and Kaplan-Meier for the survival analysis were used in this study. Statistical analyses were performed using SPSS 21.0 software (Abbott Laboratories, North Chicago, IL, USA). A P < 0.05 (two-tailed) was considered statistically significant.

**AUTHOR CONTRIBUTIONS**

Li Liu, Jin-Lin Hou and Lushan Xiao designed the study. Lushan Xiao, Wenwen Li, Qingcan Sun and Lushan Xiao performed the experiments. Lushan Xiao drafted the manuscript. Jingyuan Sun and hui-chuan Cao helped to draft the manuscript. Hongbo Zhu and Yang Song conducted the statistical analyses. Dehua Wu, Zixiao Zhou, Jie Peng and Dong Zhongyi revised the manuscript. All authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

We wish to thank all our colleagues in the Department of Infectious Diseases, Nanfang Hospital, Southern Medical University. We would like to thank Editage (www.editage.cn) for English language editing.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**FUNDING**

This work was supported by the National Nature Science Foundation of China (Grant Nos. 81773008, 81672756, 81702390, 81872399, 81972897 and 81802863), Guangdong province Universities and Colleges Pearl River Scholar Funded Scheme (2015), the Natural Science Foundation of Guangdong Province (Grant Nos. 2017A030310105, 2017A030311023, and 2018030310285), the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (Grant No. 2017J003) and Guangzhou Technology Project (No.201804010044).
REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394–424. https://doi.org/10.3322/caac.21492 PMID:30207593

2. Bodzin AS, Busuttil RW. Hepatocellular carcinoma: advances in diagnosis, management, and long term outcome. World J Hepatol. 2015; 7:1157–67. https://doi.org/10.4254/wjh.v7.i9.1157 PMID:26052391

3. Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: from diagnosis to treatment. World J Hepatol. 2015; 7:1020–29. https://doi.org/10.4254/wjh.v7.i8.1020 PMID:26052391

4. Kudo M. Systemic Therapy for Hepatocellular Carcinoma: latest Advances. Cancers (Basel). 2018; 10:10. https://doi.org/10.3390/cancers10110142 PMID:30380773

5. Zeng S, Zhang Y, Ma J, Deng G, Qu Y, Guo C, Han Y, Yin L, Cai C, Li Y, Wang G, Bonkovsky HL, Shen H. BMP4 promotes metastasis of hepatocellular carcinoma by an induction of epithelial-mesenchymal transition via upregulating ID2. Cancer Lett. 2017; 390:67–76. https://doi.org/10.1016/j.canlet.2016.12.042 PMID:28093286

6. Gao SB, Sun SL, Zheng QL, Zhang L, Zhu Y, Jin GH, Xue LX. Genetic alteration and misexpression of Polycomb group genes in hepatocellular carcinoma. Am J Cancer Res. 2015; 5:2969–79. PMID:26693053

7. Wang W, Qin JJ, Voruganti S, Nag S, Zhou J, Zhang R, and Polycomb Group. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Med Res Rev. 2015; 35:1220–67. https://doi.org/10.1002/med.21358 PMID:26227500

8. Chan HL, Beckedoff F, Zhang Y, Garcia-Huidobro J, Jiang H, Colaprico A, Bilbao D, Figueroa ME, LaCava J, Shiekhattar R, Morey L. Polycomb complexes associate with enhancers and promote oncogenic transcriptional programs in cancer through multiple mechanisms. Nat Commun. 2018; 9:3377. https://doi.org/10.1038/s41467-018-05728-x PMID:30139998

9. Gergely JE, Dorsey AE, Dimri GP, Dimri M. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells. Mol Carcinog. 2018; 57:831–41. https://doi.org/10.1002/mc.22804 PMID:29528145

10. Santanach A, Blanco E, Jiang H, Molloy KR, Sansó M, LaCava J, Morey L, Di Croce L. The Polycomb group protein CBX6 is an essential regulator of embryonic stem cell identity. Nat Commun. 2017; 8:1235. https://doi.org/10.1038/s41467-017-01464-w PMID:29089522

11. Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J, Helin K, Hansen KH. Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J. 2007; 26:1637–48. https://doi.org/10.1038/sj.emboj.7601632 PMID:17332741

12. Shen J, Li P, Shao X, Yang Y, Liu X, Feng M, Yu Q, Hu R, Wang Z. The E3 Ligase RING1 Targets p53 for Degradation and Promotes Cancer Cell Proliferation and Survival. Cancer Res. 2018; 78:359–71. https://doi.org/10.1158/0008-5472.CAN-17-1805 PMID:29187402

13. Waterfall JJ, Meltzer PS. A Non-canonical Polycomb Dependency in Synovial Sarcoma. Cancer Cell. 2018; 33:44–46. https://doi.org/10.1016/j.ccell.2018.02.013 PMID:29533779

14. Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, Song G, Mi W, Wang RF, et al. BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun. 2018; 9:500. https://doi.org/10.1038/s41467-018-02863-3 PMID:29402932

15. Chung CY, Sun Z, Mullokandov G, Bosch A, Qadeer ZA, Cihan E, Rapp Z, Parsons R, Aguirre-Ghiso JA, Farias EF, Brown BD, Gaspar-Maia A, Bernstein E. Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. Cell Rep. 2016; 16:472–86. https://doi.org/10.1016/j.celrep.2016.06.002 PMID:27343534

16. Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell. 2011; 20:563–75. https://doi.org/10.1016/j.ccr.2011.09.008 PMID:22094252

17. Wang G, Tang J, Zhan W, Zhang R, Zhang M, Liao D, Wang X, Wu Y, Kang T. CBX8 Suppresses Tumor Metastasis via Repressing Snail in Esophageal Squamous Cell Carcinoma. Theranostics. 2017; 7:3478–88.
18. Zhang CZ, Chen SL, Wang CH, He YF, Yang X, Xie D, Yun JP. CBX8 Exhibits Oncogenic Activity via AKT/β-Catenin Activation in Hepatocellular Carcinoma. Cancer Res. 2018; 78:51–63. https://doi.org/10.1158/0008-5472.CAN-17-0700 PMID:29066512

19. Yuan GJ, Chen X, Lu J, Feng ZH, Chen SL, Chen RX, Wei WS, Zhou FJ, Xie D. Chromobox homolog 8 is a predictor of muscle invasive bladder cancer and promotes cell proliferation by repressing the p53 pathway. Cancer Sci. 2017; 108:2166–75. https://doi.org/10.1111/cas.13383 PMID:28837252

20. Tang J, Wang G, Zhang M, Li FY, Sang Y, Wang B, Hu K, Wu Y, Luo R, Liao D, Cao J, Wang X, Wang L, et al. Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer. Oncotarget. 2014; 5:10778–90. https://doi.org/10.18632/oncotarget.2502 PMID:25360999

21. Lee SH, Um SJ, Kim EJ. CBX8 suppresses Sirtinol-induced premature senescence in human breast cancer cells via cooperation with SIRT1. Cancer Lett. 2013; 335:397–403. https://doi.org/10.1016/j.canlet.2013.02.051 PMID:23474493

22. Tang B, Tian Y, Liao Y, Li Z, Yu S, Su H, Zhong F, Yuan G, Wang Y, Yu H, Tomlinson S, Qiu X, He S. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis. 2019; 10:52. https://doi.org/10.1038/s41419-018-1288-0 PMID:30718464

23. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res. 2006; 34:DS35–39. https://doi.org/10.1093/nar/gki109 PMID:16381927

24. Ning G, Huang YL, Zhen LM, Xu WX, Jiao Q, Yang FJ, Wu LN, Zheng YY, Song J, Wang YS, Xie C, Peng L. Transcriptional expressions of Chromobox 1/2/3/6/8 as independent indicators for survivals in hepatocellular carcinoma patients. Aging (Albany NY). 2018; 10:3450–73. https://doi.org/10.18632/aging.101658 PMID:30481161

25. Sherr CJ. Cancer cell cycles. Science. 1996; 274:1672–77. https://doi.org/10.1126/science.274.5293.1672 PMID:8939849

26. Lee Y, Lahens NF, Zhang S, Bedont J, Field JM, Sehgal A. G1/S cell cycle regulators mediate effects of circadian dysregulation on tumor growth and provide targets for timed anticancer treatment. PLoS Biol. 2019; 17:e3000228. https://doi.org/10.1371/journal.pbio.3000228 PMID:31039152

27. Peyrestable M, Prével C, Pellerano M, Morris MC. Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors. Cancers (Basel). 2015; 7:179–237. https://doi.org/10.3390/cancers7010179 PMID:25625291

28. El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirole F, Mathers J, Khan D, Kyle AH, Baker JH, LePard NE, et al. Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis. Cancer Cell. 2015; 27:682–97. https://doi.org/10.1016/j.ccell.2015.04.003 PMID:25965573

29. Maurya PK, Mishra A, Yadav BS, Singh S, Kumar P, Chaudhary A, Srivastava S, Murugesan SN, Mani A. Role of Y Box Protein-1 in cancer: as potential biomarker and novel therapeutic target. J Cancer. 2017; 8:1900–07. https://doi.org/10.7150/jca.17689 PMID:28819388

30. Lu J, Li X, Wang F, Guo Y, Huang Y, Zhu H, Wang Y, Lu Y, Wang Z. YB-1 expression promotes pancreatic cancer metastasis that is inhibited by microRNA-216a. Exp Cell Res. 2017; 359:319–26. https://doi.org/10.1016/j.yexcr.2017.07.039 PMID:28782557

31. Zhao X, Liu Y, Yu S. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker. Biochim Biophys Acta Mol Basis Dis. 2017; 1863:1805–16. https://doi.org/10.1016/j.bbadis.2017.04.014 PMID:28428004

32. Miao X, Wu Y, Wang Y, Zhu X, Yin H, He Y, Li C, Liu Y, Lu X, Chen Y, Shen R, Xu X, He S. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma. Exp Cell Res. 2016; 346:157–66. https://doi.org/10.1016/j.yexcr.2016.07.003 PMID:27397581

33. Maier E, Attenberger F, Tiwari A, Lettau K, Rebholz S, Jehnichenbacher B, Schaller M, Gani C, Toulany M. Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells. Cancers (Basel). 2019; 11:11. https://doi.org/10.3390/cancers11040562 PMID:31010234
34. Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019; 110:1536–43.
https://doi.org/10.1111/cas.14006
PMID:30903644

35. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018; 19:649–59.
https://doi.org/10.1016/S1470-2045(18)30145-1
PMID:29650362

36. Wu S, Fatkhutdinov N, Fukumoto T, Bitler BG, Park PH, Kossenkov AV, Trizzino M, Tang HY, Zhang L, Gardini A, Speicher DW, Zhang R. SWI/SNF catalytic subunits’ switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells. Nat Commun. 2018; 9:4116.
https://doi.org/10.1038/s41467-018-06656-6
PMID:30297712

37. Genta S, Pirosa MC, Stathis A. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer. Curr Oncol Rep. 2019; 21:13.
https://doi.org/10.1007/s11912-019-0762-x
PMID:30715616

38. Huang S, Wang Z, Zhou J, Huang J, Zhou L, Luo J, Wan YY, Long H, Zhu B. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. Cancer Res. 2019; 79:2009–20.
https://doi.org/10.1158/0008-5472.CAN-18-2395
PMID:30737232

39. Velcheti V, Wong KK, Saunthararajah Y. EZH2 Inhibitors: Take It EZy, It Is All About Context. Cancer Discov. 2019; 9:472–75.
https://doi.org/10.1158/2159-8290.cd-19-0090
PMID:30936220

40. Lue JK, Prabhu SA, Liu Y, Gonzalez Y, Verma A, Mundi PS, Abshiru N, Camarillo JM, Mehta S, Chen E, Qiao C, Nandakumar R, Cremers S, et al. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas. Clin Cancer Res. 2019; 25:5271–83.
https://doi.org/10.1158/1078-0432.CCR-18-3989
PMID:30979734

41. Zhang DY, Zou XJ, Cao CH, Zhang T, Lei L, Qi XL, Liu L, Wu DH. Identification and Functional Characterization of Long Non-coding RNA MIR22HG as a Tumor Suppressor for Hepatocellular Carcinoma. Theranostics. 2018; 8:3751–65.
https://doi.org/10.7150/thno.22493 PMID:30083257

42. Hou Z, Zhao W, Zhou J, Shen L, Zhan P, Xu C, Chang C, Bi H, Zou J, Yao X, Huang R, Yu L, Yan J. A long noncoding RNA Sox2ot regulates lung cancer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol. 2014; 53:380–88.
https://doi.org/10.1016/j.biocel.2014.06.004
PMID:24927902

43. Gómez-Maldonado L, Tiana M, Roche O, Prado-Cabrero A, Jensen L, Fernandez-Barral A, Guijarro-Muñoz I, Favaro E, Moreno-Bueno G, Sanz L, Aragones J, Harris A, Volpert O, et al. EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. Oncogene. 2015; 34:2609–20.
https://doi.org/10.1038/onc.2014.200 PMID:25023702

44. Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep. 2018; 8:9227.
https://doi.org/10.1038/s41598-018-27521-y PMID:29907753
SUPPLEMENTARY MATERIALS

Supplementary Methods

Plasmid construction and transient transfection

Flag-CBX8 plasmid (Catalog Number: CH853665) was purchased from Shandong Wei Zhen Biotechnology Co. Ltd (China). Flag-YBX1 and GFP-CBX8 were purchased from Shanghai Ji Kai Biotechnology Co., Ltd (China). Cells seeded overnight were transiently transfected with plasmids or control vectors (empty vectors) at 90% cell confluence using Lipofectamine 3000 (Invitrogen, Carlsbad, CA). After 48 h, cells were harvested for the following assays.

Cell counting kit-8 (CCK-8) assays

Cellular proliferation capacity was tested with Cell Counting Kit 8 (CCK-8) assay (Dojindo, Kumamoto, Japan) following the manufacturer’s protocol. 1×10^3 cells per well were seeded in 96-well plate and grown for the given time points. 24 hours later, 10μl CCK-8 reagent was added to each plate, and cultured for another 2 hours at 37 °C. Optical density was test at 450nm. All experiments were performed in triplicate.

5-ethynyl-20-deoxyuridine (EdU) incorporation assays

MHCC-97H, SK-Hep1 and Huh7 cells seeded in 24-well plates were cultured in a humidified incubator for 12h. Cells were transiently transfected with vectors or siRNAs 12h later, according to the protocol. EdU Cell Proliferation Assay Kit (RiboBio, GUANZHOU, China) was used to detect the cellular proliferation after 48h. Briefly, fixed MHCC-97H, SK-Hep1 and Huh7 cells were stained with EdU following the recommendations after incubation with 50μM EdU. The ratio of EdU positive cells to total Hoechst positive cells was regarded as the EdU incorporation rate.

RNA interference

Small interfering RNAs were used in the current study to silence human CBX8 or YBX1 gene expression. All target sequences for CBX8 and YBX1 were synthesized by RiboBio Company (Ribobio, GUANZHOU, China). Randomly generated sequence, without sense, was used as a negative control (Scramble). Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) was used to perform transfection assays.

Western blot

Total protein was extracted using radioimmunoprecipitation (RIPA) assay buffer (Cell signaling Technology, Boston, MA, USA). The protein lysates were separated on a 12% SDS-polyacrylamide gel, and transferred onto polyvinylidene fluoride (Millipore, Bedford, MA, USA) membranes. After blocking with 5% BSA for 1 h at room temperature, the membranes were incubated with primary antibodies overnight at 4 °C. After washing, the membranes were incubated with the corresponding secondary antibodies conjugated to horseradish peroxidase. The membrane signals were detected using a commercial Excellent Chemiluminescent Substrate (ECL) kit (Pierce, Rockford, IL, USA). ImageJ software was used to analyze the band intensity of western blotting and the normalization. The primary antibodies are shown in Supplementary Table 1.

Co-immunoprecipitation (Co-IP)

Proteins were extracted using immunoprecipitation assay buffer supplemented with a protease inhibitor cocktail. Primary antibody (anti-Flag: 5 μg/ml) was added to the lysate for 2.5 h. Protein A/G beads were added and the lysates incubated for an additional 2 h. Precipitated proteins were dissolved in sodium dodecyl sulfate (SDS) loading buffer and fractionated by SDS polyacrylamide gel electrophoresis.

Gene set enrichment analysis (GSEA)

GSEA was performed to confirm which gene sets or signatures were correlated with CBX8 or YBX1 expression in the TCGA dataset. The genome-wide expression profiles, including 372 samples, were downloaded from the TCGA dataset. Among these samples, a total of 351 samples with CBX8 or YBX1-expression data were entered for GSEA after being split into two groups (CBX8 low- or high-expression groups; YBX1 low- or high-expression groups). The GSEA software (GSEA v. 2.0, http://www.broadinstitute.org/gsea) was utilized to test whether members of the gene sets or signatures were randomly distributed at the top or bottom of the ranking (genes from patients were ranked based on the correlation between CBX8 or YBX1 expression). Once most members of a gene set were positively correlated with low expression of CBX8 or YBX1, the gene set was considered as having been correlated.

Real time quantitative polymerase chain reaction (qRT-PCR)

TRizol® reagent (Invitrogen) was used for the extraction of total RNAs. First-strand cDNA was synthesized by the PrimeScript™ 1st Strand cDNA Synthesis Kit (TaKaRa, Tokyo, Japan). Real-time PCR was carried out using SYBR® Green PCR kit (TaKaRa). Primers are shown in Supplementary Table 2.
Lentiviral construction and cell transfection

The sh-CBX8 was obtained from Genechem Company Ltd. (Shanghai, China) and was used to knockdown CBX8 expression. A negative control lentiviral vector containing non-silencing short hairpin RNA was used. Huh7, MHCC-97H, and SK-Hep-1 cells were infected with either the lentiviral vectors encoding specific short hairpin RNA sequences or the negative control vector. The efficiencies of RNA interference were determined by western blot.
Supplementary Figures

Supplementary Figure 1. CBX8 positively correlates with the cell cycle signaling pathway. (A) Cell cycle-related gene mRNA levels in CBX8-knockdown Huh7 cells, as detected by q-RT-PCR.

Supplementary Figure 2. CBX8 interacts with YBX1. (A–C) Correlation between CBX8 mRNA and ILF3, TFCP2, and UBE2S mRNA in TCGA cohort. (D) Huh7 Cells were transfected with Flag-CBX8 overexpression vector for 48 h. An IP assay, using anti-Flag antibody, was used to detect the binding of CBX8 and ILF3, TFCP2, UBE2S.
Supplementary Figure 3. CBX8 increase levels of CyclinD1 through YBX1. (A–B) Both protein and mRNA levels of CyclinD1 in CBX8-overexpressing or YBX1-knock-down SK-Hep1 cells, as detected by western blotting and q-RT-PCR. (C) Protein levels of CyclinD1 in CBX8-knock-down or YBX1-overexpressing Huh7 cells as detected by western blotting.
Supplementary Figure 4. CBX8 overexpression promotes cell proliferation. (A) Cell proliferation was evaluated by the CCK-8 assay. (B–C) Effect of CBX8 on cell proliferation, as measured by EDU assays *P < 0.05; **P < 0.01; ***P < 0.001.
Supplementary Figure 5. Knockdown of CBX8 dramatically decreases cell proliferation in vitro. (A–C) Cell proliferation was evaluated by the CCK-8 assay. (D–E) Effect of CBX8 on cell proliferation, as measured by EdU assays *P < 0.05; **P < 0.01; ***P < 0.001.
Supplementary Figure 6. Knockdown of CBX8 dramatically decreases cell proliferation in vivo (A) Representative images of tumors formed in nude mice injected subcutaneously with CBX8–silenced SK-Hep-1 cells. (B) Tumor weights (**P < 0.001). (C) Tumors induced by CBX8 silencing in SK-Hep-1 cells (**P < 0.001) showed markedly lower growth rates than control cells.
Supplementary Figure 7. CBX8 promotes HCC cell proliferation through YBX1. (A–D) Cell proliferation, as detected by EdU assays. **p < 0.01; ***p < 0.001.
Supplementary Figure 8. CBX8 expression in human cancers (A) Relative CBX8 mRNA expression determined by RNA sequencing in human cancers from TCGA data (http://cancergenome.nih.gov/) using the GCBI website (https://www.gcbi.com.cn).
Supplementary Figure 9. The prognostic value of CBX8 in HCC. (A–I) Stratified analysis showed the correlation of CBX8 expression and overall survival in indicated groups in HCC from TCGA data using the Kaplan Meier-plotter website (http://kmplot.com/analysis/).
Supplementary Figure 10. YBX1 expression is up-regulated in HCC and is correlated with prognosis. (A–B) Expression of YBX1 in the GSE14520 cohort1 ($P < 0.001$) and GSE14520 cohort2 ($P < 0.05$). (C, D) Kaplan-Meier analysis of the overall and disease-free survival in the TCGA cohort based on YBX1 expression.
Supplementary Figure 11. The prognostic value of YBX1 in HCC. (A–I) Stratified analysis showed the correlation of YBX1 expression and overall survival in indicated groups in HCC from TCGA data using the Kaplan Meier-plotter website (http://kmplot.com/analysis/).
Supplementary Tables

Supplementary Table 1. Information on antibodies used in this study.

| Antibody          | WB | specificity        | Company                      |
|-------------------|----|--------------------|------------------------------|
| CBX8 (ab70796)    | 1:1000 | Rabbit Polyclonal  | Abcam                        |
| YBX1 (20339-1-AP) | 1:500 | Rabbit Polyclonal  | Proteintech                  |
| Flag (F1804)      | 1:200 | Mouse monoclonal   | Sigma                        |
| CyclinD1 (SC8396) | 1:200 | Mouse monoclonal   | Santa Cruz Biotechnology     |
| UBE2S (14115-1-AP)| 1:500 | Rabbit Polyclonal  | Proteintech                  |
| ILF3 (sc-136197) | 1:200 | Mouse monoclonal   | Santa Cruz Biotechnology     |
| TFCP2 (A5555)     | 1:500 | Rabbit Polyclonal  | ABclonal                     |
| β-actin(AC026)    | 1:7500 | Mouse monoclonal   | ABclonal                     |
| GAPDH (RM2002)    | 1:7500 | Mouse monoclonal   | Beijing Ray Antiboby Biotech |

Supplementary Table 2. Primer sequence used in this study.

| Gene     | sequence                                      |
|----------|-----------------------------------------------|
| CBX8-F   | 5’ACGAAAGGGACATGGAAT 3’                        |
| CBX8-R   | 5’ CTTGGTCCAGCTTTTTGG 3’                      |
| CCND1-F  | 5’ATGCAAACCTCAACGAC 3’                       |
| CCND1-R  | 5’TCTGTTCTCAGCAACC3’                          |
| β-actin-F| 5’ACAGAGCTCGCCTTGCC 3’                        |
| β-actin-R| 5’GATATCATCATCAGATGAGCTGG3’                   |
| CCNA1-F  | 5’ GAGAACGGGTCACGAAACA3’                      |
| CCNA1-R  | 5’ACTGTAGCCAGCACAAGCC3’                       |
| CCNB1-F  | 5’GAAACGATCTCTGCAGCA3’                        |
| CCNB1-R  | 5’ACACACCAGCAGAAAAC3’                         |
| CCNE1-F  | 5’GCAGGATCCAGATGAAATG3’                       |
| CCNE1-R  | 5’TAAATCCAGCTCTGGCACTTT3’                     |
| CDK2-F   | 5’CGAGGTGCTGGAAATCC3’                         |
| CDK2-R   | 5’CCAGAGCTGGAAAGATCC3’                        |
| CDK1-F   | 5’TCCCTTTGGCCTCCAGCA3’                        |
| CDK1-R   | 5’CAATCGGAGTCCGGTGAGAC3’                      |